Download the Article: 'Tackling biosimilars – how to handle the threat to pharma brands'

Recently, Blue Latitude Health worked with a global pharmaceutical brand to develop a strategy for dealing with the introduction of biosimilars to the market. Their product, a treatment in the gastroenterology therapy area, had recently come off patent and a biosimilar was about to launch. Strategy Consultant Mark Assenti talks through three key points for developing a strategy to tackle biosimilars.

Please enter your details so we can email you the content


Our content has moved

We’re posting all new articles on our parent website fishawack.com

Fishawack Health launches Delta Magazine

Our parent company Fishawack Health has launched a new magazine with a first issue unpacking rare disease.

In the precision medicine era, the line between products and services is blurred

Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?

SIGN UP TO OUR NEWSLETTER TO RECEIVE

  • Our latest articles on industry trends
  • Access to downloadable resources
  • Updates on pharma events and career opportunities
SIGN UP NOW